ArticlePloS one2026
Vimentin neutralizing antibody ameliorate inflammatory bowel disease by inhibiting fibrosis and inflammatory cell death.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is characterized by chronic inflammation intertwined with fibrosis and increased necroptosis. Vimentin, an intermediate filament protein closely associated with fibrosis and several inflammatory pathways, is elevated in IBD tissues. We conducted experiments to determine the effect of neutralization of extracellular vimentin with an anti-vimentin antibody (Ab) on the pathogenesis of IBD.
methodsIBD was mimicked in a 7-week C57BL6 mice by mixing 3% dextran sodium sulfate (DSS) in autoclaved drinking water for five days. Anti-vimentin Ab was intraperitoneally injected with a concentration of 3 milligrams per kilogram repeatedly in a three-day interval simultaneously with DSS administration.
resultsIn dextran sodium sulfate (DSS)-induced colitis mice, the anti-vimentin Ab decreased the levels of total and cell-surface vimentin in colon tissues compared to control-treated mice. In DSS-induced colitis mice, treatment with the anti-vimentin Ab improved body weight loss and colon shortening, thereby reducing the severity of DSS-induced colitis. In addition, the anti-vimentin Ab reduced the number of cells expressing fibrosis markers, inflammatory cytokines, and necroptotic markers in colon tissues of DSS-induced colitis mice. In CCD-18CO human colon epithelial cells, the increases in the levels of fibrosis markers caused by TGFβ were enhanced by vimentin protein stimulation and the anti-vimentin Ab reduced the levels of fibrosis-related factors.
conclusionThis is the first report of the therapeutic effect of an anti-vimentin Ab on the pathogenic mechanisms of IBD. Further studies are needed to confirm its therapeutic potential in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.